Follow
Nijman
Nijman
Unknown affiliation
Verified email at umcg.nl
Title
Cited by
Cited by
Year
B lymphocytes secrete antigen-presenting vesicles.
G Raposo, HW Nijman, W Stoorvogel, R Liejendekker, CV Harding, ...
The Journal of experimental medicine 183 (3), 1161-1172, 1996
35251996
ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up
N Colombo, C Creutzberg, F Amant, T Bosse, A GonzŠlez-MartŪn, ...
International Journal of Gynecologic Cancer 26 (1), 2016
15272016
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
MJM Gooden, GH de Bock, N Leffers, T Daemen, HW Nijman
British journal of cancer 105 (1), 93-103, 2011
12052011
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer
N Leffers, MJM Gooden, RA de Jong, BN Hoogeboom, KA ten Hoor, ...
Cancer Immunology, Immunotherapy 58 (3), 449-459, 2009
5102009
Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer—combined analysis of the PORTEC cohorts
E Stelloo, RA Nout, EM Osse, IJ JŁrgenliemk-Schulz, JJ Jobsen, ...
Clinical cancer research 22 (16), 4215-4224, 2016
4612016
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre†…
SM de Boer, ME Powell, L Mileshkin, D Katsaros, P Bessette, ...
The lancet oncology 19 (3), 295-309, 2018
4082018
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative
E Stelloo, T Bosse, RA Nout, HJ MacKay, DN Church, HW Nijman, ...
Modern pathology 28 (6), 836-844, 2015
3432015
In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53
JGA Houbiers, HW Nijman, SH Van Der Burg, JW Drijfhout, P Kenemans, ...
European journal of immunology 23 (9), 2072-2077, 1993
3231993
Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial
RA Nout, H Putter, IM JŁrgenliemk-Schulz, JJ Jobsen, LCHW Lutgens, ...
Journal of Clinical Oncology 27 (21), 3547-3556, 2009
3042009
Identification of peptide sequences that potentially trigger HLA‐A2. 1‐restricted cytotoxic T lymphocytes
HW Nijman, JGA Houbiers, MPM Vierboom, SH van der Burg, ...
European journal of immunology 23 (6), 1215-1219, 1993
2741993
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a†…
SM de Boer, ME Powell, L Mileshkin, D Katsaros, P Bessette, ...
The lancet oncology 20 (9), 1273-1285, 2019
2672019
Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
MPM Vierboom, HW Nijman, R Offringa, EIH Voort, T Hall, L Broek, ...
The Journal of experimental medicine 186 (5), 695-704, 1997
2661997
POLE proofreading mutations elicit an antitumor immune response in endometrial cancer
IC van Gool, FA Eggink, L Freeman-Mills, E Stelloo, E Marchi, M de Bruyn, ...
Clinical Cancer Research 21 (14), 3347-3355, 2015
2542015
Lymphvascular space involvement: an independent prognostic factor in endometrial cancer
JM BriŽt, H Hollema, N Reesink, JG Aalders, MJE Mourits, A Klaske, ...
Gynecologic oncology 96 (3), 799-804, 2005
2542005
Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells.
HW Nijman, MJ Kleijmeer, MA Ossevoort, VM Oorschot, MP Vierboom, ...
The Journal of experimental medicine 182 (1), 163-174, 1995
2501995
Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy
A Leůn-Castillo, SM De Boer, ME Powell, LR Mileshkin, HJ Mackay, ...
Journal of Clinical Oncology 38 (29), 3388, 2020
2492020
Myeloid derived suppressor cells—an overview of combat strategies to increase immunotherapy efficacy
O Draghiciu, J Lubbers, HW Nijman, T Daemen
Oncoimmunology 4 (1), e954829, 2015
2452015
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study
E Domingo, L Freeman-Mills, E Rayner, M Glaire, S Briggs, L Vermeulen, ...
The lancet Gastroenterology & hepatology 1 (3), 207-216, 2016
2202016
Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer
RA De Jong, N Leffers, HM Boezen, KA Ten Hoor, AGJ van der Zee, ...
Gynecologic oncology 114 (1), 105-110, 2009
2152009
HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes
M Gooden, M Lampen, ES Jordanova, N Leffers, JB Trimbos, ...
Proceedings of the National Academy of Sciences 108 (26), 10656-10661, 2011
2072011
The system can't perform the operation now. Try again later.
Articles 1–20